|Bid||1.41 x 2200|
|Ask||1.75 x 200|
|Day's Range||1.50 - 1.55|
|52 Week Range||0.83 - 4.75|
|PE Ratio (TTM)||-1.00|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||19.00|
NEW YORK, Sept. 5, 2017 /PRNewswire/ -- Hoth Therapeutics Inc., a Nevada corporation ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, announced today the addition of Dr. Andrew Herr, PhD, to the Company's Technology Advisory Board. The Technology Advisory Board was formed to assist the Company in developing the BioLexa Platform. The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati.
NEW YORK, Aug. 15, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (SPEX), an intellectual property development company committed to the fostering of technology, today announced the addition of Dr. Scott T. Tagawa to the Company's Technology Advisory Board. The Technology Advisory Board was formed to assist the Company in evaluating potential opportunities in the biopharmaceutical arena. Dr. Scott T. Tagawa, MD, MS is the Richard A. Stratton Associate Professor in Hematology and Oncology and an Associate Professor of Clinical Medicine and of Clinical Urology at Weill Cornell Medicine.
NEW YORK, Aug. 2, 2017 /PRNewswire/ -- Spherix Incorporated (SPEX) an intellectual property development company committed to fostering of technology, today issued a letter to shareholders. It is with great pleasure that I take this opportunity to update you on recent events at the Company and describe in greater detail our strategic path forward. The fundamentals at Spherix are stronger than they have been in recent memory and our path to value creation is moving forward with precision and focus.